

Julien Mendlewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5330079/publications.pdf>

Version: 2024-02-01

31
papers

872
citations

567281

15
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1474
citing authors

#	ARTICLE	IF	CITATIONS
1	European Group for the Study of Resistant Depression (GSRD) "Where have we gone so far: Review of clinical and genetic findings. European Neuropsychopharmacology, 2012, 22, 453-468.	0.7	111
2	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. European Neuropsychopharmacology, 2015, 25, 441-453.	0.7	77
3	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. Journal of Psychiatric Research, 2017, 91, 1-13.	3.1	77
4	Refining Prediction in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2018, 79, 16m11385.	2.2	76
5	A New Prediction Model for Evaluating Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2017, 78, 215-222.	2.2	73
6	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers "A pharmacoepidemiological cross-sectional multicenter study. European Neuropsychopharmacology, 2016, 26, 1960-1971.	0.7	50
7	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). European Neuropsychopharmacology, 2018, 28, 752-760.	0.7	47
8	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	2.8	44
9	Depression across mood disorders: review and analysis in a clinical sample. Comprehensive Psychiatry, 2012, 53, 24-38.	3.1	34
10	Psychotic Features in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	28
11	Towards achieving remission in the treatment of depression. Dialogues in Clinical Neuroscience, 2008, 10, 371-375.	3.7	27
12	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109638.	4.8	20
13	Genetic refinement and physical mapping of a chromosome 18q candidate region for bipolar disorder. European Journal of Human Genetics, 1999, 7, 427-434.	2.8	19
14	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes "Results from a cross-sectional European multicenter study. European Neuropsychopharmacology, 2017, 27, 625-632.	0.7	19
15	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. International Clinical Psychopharmacology, 2010, 25, 297-301.	1.7	18
16	Comorbid hypertension in patients with major depressive disorder "Results from a European multicenter study. European Neuropsychopharmacology, 2019, 29, 777-785.	0.7	18
17	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. Depression and Anxiety, 2021, 38, 896-906.	4.1	18
18	Melancholic features in major depression "a European multicenter study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110285.	4.8	17

#	ARTICLE	IF	CITATIONS
19	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.7	15
20	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.7	14
21	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	3.1	14
22	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	3.2	14
23	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 782-787.	2.1	10
24	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	1.5	7
25	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	2.1	5
26	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	4.1	4
27	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	4.1	3
28	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	4.8	3
29	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 46-52.	2.0	2
30	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	2.1	2
31	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	2.4	1